SMS Pharmaceuticals Limited
SMS Pharmaceuticals Limited (SMSPHARMA.NS) Stock Competitors & Peer Comparison
See (SMSPHARMA.NS) competitors and their performances in Stock Market.
Peer Comparison Table: Drug Manufacturers - General Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| SMSPHARMA.NS | ₹399.20 | +2.35% | 37.4B | 39.84 | ₹10.02 | +0.10% |
| CIPLA.NS | ₹1,215.90 | +1.12% | 982.2B | 21.61 | ₹56.27 | +1.33% |
| CIPLA.BO | ₹1,215.80 | +1.13% | 982.1B | 21.63 | ₹56.20 | +1.33% |
| ABBOTINDIA.BO | ₹25,853.30 | +0.75% | 549.4B | 36.39 | ₹710.49 | +1.85% |
| ABBOTINDIA.NS | ₹25,850.00 | +0.72% | 549.3B | 36.10 | ₹716.05 | +1.85% |
| GLAXO.BO | ₹2,354.75 | +1.01% | 398.9B | 41.83 | ₹56.30 | +2.31% |
| GLAXO.NS | ₹2,354.30 | +0.90% | 398.8B | 39.02 | ₹60.33 | +2.31% |
| GLAND.BO | ₹1,729.20 | +0.89% | 284.9B | 33.67 | ₹51.36 | +1.05% |
| GLAND.NS | ₹1,728.50 | +0.70% | 284.8B | 33.34 | ₹51.84 | +1.05% |
| PFIZER.NS | ₹4,835.70 | +1.18% | 221.2B | 25.88 | ₹186.82 | +3.45% |
Stock Comparison
SMSPHARMA.NS vs CIPLA.NS Comparison April 2026
SMSPHARMA.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMSPHARMA.NS stands at 37.4B. In comparison, CIPLA.NS has a market cap of 982.2B. Regarding current trading prices, SMSPHARMA.NS is priced at ₹399.20, while CIPLA.NS trades at ₹1,215.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMSPHARMA.NS currently has a P/E ratio of 39.84, whereas CIPLA.NS's P/E ratio is 21.61. In terms of profitability, SMSPHARMA.NS's ROE is +0.14%, compared to CIPLA.NS's ROE of +0.15%. Regarding short-term risk, SMSPHARMA.NS is more volatile compared to CIPLA.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SMSPHARMA.NS.Check CIPLA.NS's competition here
SMSPHARMA.NS vs CIPLA.BO Comparison April 2026
SMSPHARMA.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMSPHARMA.NS stands at 37.4B. In comparison, CIPLA.BO has a market cap of 982.1B. Regarding current trading prices, SMSPHARMA.NS is priced at ₹399.20, while CIPLA.BO trades at ₹1,215.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMSPHARMA.NS currently has a P/E ratio of 39.84, whereas CIPLA.BO's P/E ratio is 21.63. In terms of profitability, SMSPHARMA.NS's ROE is +0.14%, compared to CIPLA.BO's ROE of +0.15%. Regarding short-term risk, SMSPHARMA.NS is more volatile compared to CIPLA.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SMSPHARMA.NS.Check CIPLA.BO's competition here
SMSPHARMA.NS vs ABBOTINDIA.BO Comparison April 2026
SMSPHARMA.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMSPHARMA.NS stands at 37.4B. In comparison, ABBOTINDIA.BO has a market cap of 549.4B. Regarding current trading prices, SMSPHARMA.NS is priced at ₹399.20, while ABBOTINDIA.BO trades at ₹25,853.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMSPHARMA.NS currently has a P/E ratio of 39.84, whereas ABBOTINDIA.BO's P/E ratio is 36.39. In terms of profitability, SMSPHARMA.NS's ROE is +0.14%, compared to ABBOTINDIA.BO's ROE of +0.38%. Regarding short-term risk, SMSPHARMA.NS is more volatile compared to ABBOTINDIA.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SMSPHARMA.NS.Check ABBOTINDIA.BO's competition here
SMSPHARMA.NS vs ABBOTINDIA.NS Comparison April 2026
SMSPHARMA.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMSPHARMA.NS stands at 37.4B. In comparison, ABBOTINDIA.NS has a market cap of 549.3B. Regarding current trading prices, SMSPHARMA.NS is priced at ₹399.20, while ABBOTINDIA.NS trades at ₹25,850.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMSPHARMA.NS currently has a P/E ratio of 39.84, whereas ABBOTINDIA.NS's P/E ratio is 36.10. In terms of profitability, SMSPHARMA.NS's ROE is +0.14%, compared to ABBOTINDIA.NS's ROE of +0.38%. Regarding short-term risk, SMSPHARMA.NS is more volatile compared to ABBOTINDIA.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SMSPHARMA.NS.Check ABBOTINDIA.NS's competition here
SMSPHARMA.NS vs GLAXO.BO Comparison April 2026
SMSPHARMA.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMSPHARMA.NS stands at 37.4B. In comparison, GLAXO.BO has a market cap of 398.9B. Regarding current trading prices, SMSPHARMA.NS is priced at ₹399.20, while GLAXO.BO trades at ₹2,354.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMSPHARMA.NS currently has a P/E ratio of 39.84, whereas GLAXO.BO's P/E ratio is 41.83. In terms of profitability, SMSPHARMA.NS's ROE is +0.14%, compared to GLAXO.BO's ROE of +0.56%. Regarding short-term risk, SMSPHARMA.NS is more volatile compared to GLAXO.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SMSPHARMA.NS.Check GLAXO.BO's competition here
SMSPHARMA.NS vs GLAXO.NS Comparison April 2026
SMSPHARMA.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMSPHARMA.NS stands at 37.4B. In comparison, GLAXO.NS has a market cap of 398.8B. Regarding current trading prices, SMSPHARMA.NS is priced at ₹399.20, while GLAXO.NS trades at ₹2,354.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMSPHARMA.NS currently has a P/E ratio of 39.84, whereas GLAXO.NS's P/E ratio is 39.02. In terms of profitability, SMSPHARMA.NS's ROE is +0.14%, compared to GLAXO.NS's ROE of +0.56%. Regarding short-term risk, SMSPHARMA.NS is more volatile compared to GLAXO.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SMSPHARMA.NS.Check GLAXO.NS's competition here
SMSPHARMA.NS vs GLAND.BO Comparison April 2026
SMSPHARMA.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMSPHARMA.NS stands at 37.4B. In comparison, GLAND.BO has a market cap of 284.9B. Regarding current trading prices, SMSPHARMA.NS is priced at ₹399.20, while GLAND.BO trades at ₹1,729.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMSPHARMA.NS currently has a P/E ratio of 39.84, whereas GLAND.BO's P/E ratio is 33.67. In terms of profitability, SMSPHARMA.NS's ROE is +0.14%, compared to GLAND.BO's ROE of +0.09%. Regarding short-term risk, SMSPHARMA.NS is less volatile compared to GLAND.BO. This indicates potentially lower risk in terms of short-term price fluctuations for SMSPHARMA.NS.Check GLAND.BO's competition here
SMSPHARMA.NS vs GLAND.NS Comparison April 2026
SMSPHARMA.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMSPHARMA.NS stands at 37.4B. In comparison, GLAND.NS has a market cap of 284.8B. Regarding current trading prices, SMSPHARMA.NS is priced at ₹399.20, while GLAND.NS trades at ₹1,728.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMSPHARMA.NS currently has a P/E ratio of 39.84, whereas GLAND.NS's P/E ratio is 33.34. In terms of profitability, SMSPHARMA.NS's ROE is +0.14%, compared to GLAND.NS's ROE of +0.09%. Regarding short-term risk, SMSPHARMA.NS is more volatile compared to GLAND.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SMSPHARMA.NS.Check GLAND.NS's competition here
SMSPHARMA.NS vs PFIZER.NS Comparison April 2026
SMSPHARMA.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMSPHARMA.NS stands at 37.4B. In comparison, PFIZER.NS has a market cap of 221.2B. Regarding current trading prices, SMSPHARMA.NS is priced at ₹399.20, while PFIZER.NS trades at ₹4,835.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMSPHARMA.NS currently has a P/E ratio of 39.84, whereas PFIZER.NS's P/E ratio is 25.88. In terms of profitability, SMSPHARMA.NS's ROE is +0.14%, compared to PFIZER.NS's ROE of +0.21%. Regarding short-term risk, SMSPHARMA.NS is more volatile compared to PFIZER.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SMSPHARMA.NS.Check PFIZER.NS's competition here
SMSPHARMA.NS vs PFIZER.BO Comparison April 2026
SMSPHARMA.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMSPHARMA.NS stands at 37.4B. In comparison, PFIZER.BO has a market cap of 220.9B. Regarding current trading prices, SMSPHARMA.NS is priced at ₹399.20, while PFIZER.BO trades at ₹4,829.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMSPHARMA.NS currently has a P/E ratio of 39.84, whereas PFIZER.BO's P/E ratio is 26.34. In terms of profitability, SMSPHARMA.NS's ROE is +0.14%, compared to PFIZER.BO's ROE of +0.21%. Regarding short-term risk, SMSPHARMA.NS is more volatile compared to PFIZER.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SMSPHARMA.NS.Check PFIZER.BO's competition here
SMSPHARMA.NS vs SANOFICONR.NS Comparison April 2026
SMSPHARMA.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMSPHARMA.NS stands at 37.4B. In comparison, SANOFICONR.NS has a market cap of 103.2B. Regarding current trading prices, SMSPHARMA.NS is priced at ₹399.20, while SANOFICONR.NS trades at ₹4,479.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMSPHARMA.NS currently has a P/E ratio of 39.84, whereas SANOFICONR.NS's P/E ratio is 42.92. In terms of profitability, SMSPHARMA.NS's ROE is +0.14%, compared to SANOFICONR.NS's ROE of +0.79%. Regarding short-term risk, SMSPHARMA.NS is less volatile compared to SANOFICONR.NS. This indicates potentially lower risk in terms of short-term price fluctuations for SMSPHARMA.NS.Check SANOFICONR.NS's competition here
SMSPHARMA.NS vs MARKSANS.BO Comparison April 2026
SMSPHARMA.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMSPHARMA.NS stands at 37.4B. In comparison, MARKSANS.BO has a market cap of 79.1B. Regarding current trading prices, SMSPHARMA.NS is priced at ₹399.20, while MARKSANS.BO trades at ₹174.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMSPHARMA.NS currently has a P/E ratio of 39.84, whereas MARKSANS.BO's P/E ratio is 22.51. In terms of profitability, SMSPHARMA.NS's ROE is +0.14%, compared to MARKSANS.BO's ROE of +0.14%. Regarding short-term risk, SMSPHARMA.NS is more volatile compared to MARKSANS.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SMSPHARMA.NS.Check MARKSANS.BO's competition here
SMSPHARMA.NS vs MARKSANS.NS Comparison April 2026
SMSPHARMA.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMSPHARMA.NS stands at 37.4B. In comparison, MARKSANS.NS has a market cap of 79.1B. Regarding current trading prices, SMSPHARMA.NS is priced at ₹399.20, while MARKSANS.NS trades at ₹174.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMSPHARMA.NS currently has a P/E ratio of 39.84, whereas MARKSANS.NS's P/E ratio is 21.96. In terms of profitability, SMSPHARMA.NS's ROE is +0.14%, compared to MARKSANS.NS's ROE of +0.14%. Regarding short-term risk, SMSPHARMA.NS is more volatile compared to MARKSANS.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SMSPHARMA.NS.Check MARKSANS.NS's competition here
SMSPHARMA.NS vs SANOFI.BO Comparison April 2026
SMSPHARMA.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMSPHARMA.NS stands at 37.4B. In comparison, SANOFI.BO has a market cap of 78.8B. Regarding current trading prices, SMSPHARMA.NS is priced at ₹399.20, while SANOFI.BO trades at ₹3,421.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMSPHARMA.NS currently has a P/E ratio of 39.84, whereas SANOFI.BO's P/E ratio is 24.15. In terms of profitability, SMSPHARMA.NS's ROE is +0.14%, compared to SANOFI.BO's ROE of +0.37%. Regarding short-term risk, SMSPHARMA.NS is more volatile compared to SANOFI.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SMSPHARMA.NS.Check SANOFI.BO's competition here
SMSPHARMA.NS vs SANOFI.NS Comparison April 2026
SMSPHARMA.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMSPHARMA.NS stands at 37.4B. In comparison, SANOFI.NS has a market cap of 78.8B. Regarding current trading prices, SMSPHARMA.NS is priced at ₹399.20, while SANOFI.NS trades at ₹3,419.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMSPHARMA.NS currently has a P/E ratio of 39.84, whereas SANOFI.NS's P/E ratio is 24.13. In terms of profitability, SMSPHARMA.NS's ROE is +0.14%, compared to SANOFI.NS's ROE of +0.37%. Regarding short-term risk, SMSPHARMA.NS is more volatile compared to SANOFI.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SMSPHARMA.NS.Check SANOFI.NS's competition here
SMSPHARMA.NS vs SMSPHARMA.BO Comparison April 2026
SMSPHARMA.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMSPHARMA.NS stands at 37.4B. In comparison, SMSPHARMA.BO has a market cap of 37.3B. Regarding current trading prices, SMSPHARMA.NS is priced at ₹399.20, while SMSPHARMA.BO trades at ₹398.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMSPHARMA.NS currently has a P/E ratio of 39.84, whereas SMSPHARMA.BO's P/E ratio is 39.73. In terms of profitability, SMSPHARMA.NS's ROE is +0.14%, compared to SMSPHARMA.BO's ROE of +0.14%. Regarding short-term risk, SMSPHARMA.NS is more volatile compared to SMSPHARMA.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SMSPHARMA.NS.Check SMSPHARMA.BO's competition here
SMSPHARMA.NS vs SENORES.NS Comparison April 2026
SMSPHARMA.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMSPHARMA.NS stands at 37.4B. In comparison, SENORES.NS has a market cap of 36.1B. Regarding current trading prices, SMSPHARMA.NS is priced at ₹399.20, while SENORES.NS trades at ₹783.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMSPHARMA.NS currently has a P/E ratio of 39.84, whereas SENORES.NS's P/E ratio is 30.45. In terms of profitability, SMSPHARMA.NS's ROE is +0.14%, compared to SENORES.NS's ROE of +0.13%. Regarding short-term risk, SMSPHARMA.NS is more volatile compared to SENORES.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SMSPHARMA.NS.Check SENORES.NS's competition here
SMSPHARMA.NS vs NGLFINE.BO Comparison April 2026
SMSPHARMA.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMSPHARMA.NS stands at 37.4B. In comparison, NGLFINE.BO has a market cap of 14.4B. Regarding current trading prices, SMSPHARMA.NS is priced at ₹399.20, while NGLFINE.BO trades at ₹2,337.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMSPHARMA.NS currently has a P/E ratio of 39.84, whereas NGLFINE.BO's P/E ratio is 40.81. In terms of profitability, SMSPHARMA.NS's ROE is +0.14%, compared to NGLFINE.BO's ROE of +0.12%. Regarding short-term risk, SMSPHARMA.NS is less volatile compared to NGLFINE.BO. This indicates potentially lower risk in terms of short-term price fluctuations for SMSPHARMA.NS.Check NGLFINE.BO's competition here
SMSPHARMA.NS vs NGLFINE.NS Comparison April 2026
SMSPHARMA.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMSPHARMA.NS stands at 37.4B. In comparison, NGLFINE.NS has a market cap of 14.4B. Regarding current trading prices, SMSPHARMA.NS is priced at ₹399.20, while NGLFINE.NS trades at ₹2,331.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMSPHARMA.NS currently has a P/E ratio of 39.84, whereas NGLFINE.NS's P/E ratio is 40.80. In terms of profitability, SMSPHARMA.NS's ROE is +0.14%, compared to NGLFINE.NS's ROE of +0.12%. Regarding short-term risk, SMSPHARMA.NS is less volatile compared to NGLFINE.NS. This indicates potentially lower risk in terms of short-term price fluctuations for SMSPHARMA.NS.Check NGLFINE.NS's competition here
SMSPHARMA.NS vs TTKHLTCARE.NS Comparison April 2026
SMSPHARMA.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMSPHARMA.NS stands at 37.4B. In comparison, TTKHLTCARE.NS has a market cap of 12.5B. Regarding current trading prices, SMSPHARMA.NS is priced at ₹399.20, while TTKHLTCARE.NS trades at ₹886.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMSPHARMA.NS currently has a P/E ratio of 39.84, whereas TTKHLTCARE.NS's P/E ratio is 20.84. In terms of profitability, SMSPHARMA.NS's ROE is +0.14%, compared to TTKHLTCARE.NS's ROE of +0.06%. Regarding short-term risk, SMSPHARMA.NS is less volatile compared to TTKHLTCARE.NS. This indicates potentially lower risk in terms of short-term price fluctuations for SMSPHARMA.NS.Check TTKHLTCARE.NS's competition here
SMSPHARMA.NS vs KOPRAN.NS Comparison April 2026
SMSPHARMA.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMSPHARMA.NS stands at 37.4B. In comparison, KOPRAN.NS has a market cap of 7.1B. Regarding current trading prices, SMSPHARMA.NS is priced at ₹399.20, while KOPRAN.NS trades at ₹146.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMSPHARMA.NS currently has a P/E ratio of 39.84, whereas KOPRAN.NS's P/E ratio is 42.77. In terms of profitability, SMSPHARMA.NS's ROE is +0.14%, compared to KOPRAN.NS's ROE of +0.03%. Regarding short-term risk, SMSPHARMA.NS is less volatile compared to KOPRAN.NS. This indicates potentially lower risk in terms of short-term price fluctuations for SMSPHARMA.NS.Check KOPRAN.NS's competition here
SMSPHARMA.NS vs KOPRAN.BO Comparison April 2026
SMSPHARMA.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMSPHARMA.NS stands at 37.4B. In comparison, KOPRAN.BO has a market cap of 7.1B. Regarding current trading prices, SMSPHARMA.NS is priced at ₹399.20, while KOPRAN.BO trades at ₹146.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMSPHARMA.NS currently has a P/E ratio of 39.84, whereas KOPRAN.BO's P/E ratio is 42.73. In terms of profitability, SMSPHARMA.NS's ROE is +0.14%, compared to KOPRAN.BO's ROE of +0.03%. Regarding short-term risk, SMSPHARMA.NS is less volatile compared to KOPRAN.BO. This indicates potentially lower risk in terms of short-term price fluctuations for SMSPHARMA.NS.Check KOPRAN.BO's competition here